--- title: "ENDRA Life Sciences (NDRA) news: offering and merger" url: "https://aibio.space/companies/endra-life-sciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NDRA offering and merger news: ENDRA expects $3.8 million from private placement of stock and warrants. ENDRA Life Sciences Inc." --- NDRA ENDRA Life Sciences Inc. NASDAQ · United States # ENDRA Life Sciences (NDRA) news NDRA offering and merger news Mergers · 2026-10-01 ## [ENDRA amends merger agreement with ASP Isotopes and Renergen](https://aibio.space/news/endra-amends-merger-agreement-asp-isotopes-renergen/) The October 1, 2026 amendment sets a $3,800,002.59 minimum cash condition, drops the classified board requirement, and lets Renergen borrow up to $120 million from ASP Isotopes. ## Latest ENDRA Life Sciences news 1. 2026-08-17 Mergers [ENDRA reports second quarter 2026 results and merger progress](https://aibio.space/news/endra-reports-second-quarter-2026-results-merger-progress/) ENDRA reported net income of approximately $160,000 for the second quarter of 2026 and said it expects the Noble Africa merger to close in the fourth quarter of 2026. 2. 2026-07-09 Listings [ENDRA regains Nasdaq stockholders' equity compliance](https://aibio.space/news/endra-regains-nasdaq-stockholders-equity-compliance/) Nasdaq told ENDRA on July 8, 2026 that it regained compliance with the $2,500,000 minimum stockholders' equity requirement, but the company will be under a one-year panel monitor. 3. 2026-05-28 Financings [ENDRA expects $3.8 million from private placement of stock and warrants](https://aibio.space/news/endra-expects-3-8-million-private-placement-stock-warrants/) ENDRA agreed on May 27, 2026 to sell 578,387 shares or prefunded warrants, with common warrants for up to 1,156,774 shares, through sole placement agent Lucid Capital Markets, LLC. ## ENDRA Life Sciences at a glance - **Ticker**: NDRA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $1.7 million ### Related companies - [Baird Medical Investment Holdings](https://aibio.space/companies/baird-medical-investment/) NASDAQ: BDMD - [Trulieve Cannabis](https://aibio.space/companies/trulieve-cannabis/) NYSE: TRLV - [NIKA PHARMACEUTICALS, INC](https://aibio.space/companies/nika-pharmaceuticals/) OTC: NIKA - [China Foods Holdings](https://aibio.space/companies/china-foods/) OTC: CFOO - [Hyperfine](https://aibio.space/companies/hyperfine/) NASDAQ: HYPR - [NEXGEL, INC.](https://aibio.space/companies/nexgel/) NASDAQ: NXGL - [RESMED INC](https://aibio.space/companies/resmed/) NYSE: RMD - [Green Planet Bio Engineering Co.](https://aibio.space/companies/green-planet-bio-engineering/) OTC: GPLB ### Also on NASDAQ - [Envoy Medical](https://aibio.space/companies/envoy-medical/) COCH - [Sol-Gel Technologies](https://aibio.space/companies/sol-gel-technologies/) SLGL - [Editas Medicine](https://aibio.space/companies/editas-medicine/) EDIT - [OKYO Pharma](https://aibio.space/companies/okyo-pharma/) OKYO - [Beyond Air](https://aibio.space/companies/beyond-air/) XAIR - [Pulmatrix](https://aibio.space/companies/pulmatrix/) PULM ## ENDRA Life Sciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$1.8 million](https://www.sec.gov/Archives/edgar/data/1681682/000121390026037617/) | [$3.2 million](https://www.sec.gov/Archives/edgar/data/1681682/000121390026037617/) | | Net income (loss) | [-$7.0 million](https://www.sec.gov/Archives/edgar/data/1681682/000121390026037617/) | [-$11.5 million](https://www.sec.gov/Archives/edgar/data/1681682/000121390026037617/) | | Cash from operations | [-$5.2 million](https://www.sec.gov/Archives/edgar/data/1681682/000121390026037617/) | [-$7.4 million](https://www.sec.gov/Archives/edgar/data/1681682/000121390026037617/) | | Cash and equivalents | [$762,365](https://www.sec.gov/Archives/edgar/data/1681682/000121390026090027/) | [$3.2 million](https://www.sec.gov/Archives/edgar/data/1681682/000121390026090027/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about ENDRA Life Sciences Has ENDRA Life Sciences raised money recently? Our latest story on this, dated May 28, 2026: "ENDRA expects $3.8 million from private placement of stock and warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/endra-expects-3-8-million-private-placement-stock-warrants/). Is ENDRA Life Sciences involved in a merger or acquisition? Our latest story on this, dated Oct 1, 2026: "ENDRA amends merger agreement with ASP Isotopes and Renergen". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/endra-amends-merger-agreement-asp-isotopes-renergen/). What is the ticker symbol of ENDRA Life Sciences? ENDRA Life Sciences Inc. trades under the ticker NDRA on NASDAQ. Where is ENDRA Life Sciences listed? ENDRA Life Sciences Inc. is listed on NASDAQ. Which country or territory is ENDRA Life Sciences listed under? Our directory records ENDRA Life Sciences Inc. under United States. Does aibio.space cover ENDRA Life Sciences? aibio.space lists ENDRA Life Sciences Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Is ENDRA Life Sciences profitable? ENDRA Life Sciences Inc. reported a net loss of $7.0 million for the fiscal year ended Dec 31, 2025, and used $5.2 million of cash in operations, per its annual report to the SEC. How much does ENDRA Life Sciences spend on research and development? $1.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does ENDRA Life Sciences have? $1.7 million in cash at Jun 30, 2026, per its 10-Q. What is the latest ENDRA Life Sciences (NDRA) stock news? Our latest story on ENDRA Life Sciences, dated Oct 1, 2026: "ENDRA amends merger agreement with ASP Isotopes and Renergen". The October 1, 2026 amendment sets a $3,800,002.59 minimum cash condition, drops the classified board requirement, and lets Renergen borrow up to $120 million from ASP Isotopes. [Source](https://aibio.space/news/endra-amends-merger-agreement-asp-isotopes-renergen/). Is ENDRA Life Sciences at risk of delisting? Our latest listing story, dated Jul 9, 2026: "ENDRA regains Nasdaq stockholders' equity compliance". Nasdaq told ENDRA on July 8, 2026 that it regained compliance with the $2,500,000 minimum stockholders' equity requirement, but the company will be under a one-year panel monitor. [Source](https://aibio.space/news/endra-regains-nasdaq-stockholders-equity-compliance/). How can I follow ENDRA Life Sciences (NDRA) news? Press Follow on this page to add ENDRA Life Sciences to your Following list, or subscribe to the aibio.space newsletter. We have published 4 stories naming ENDRA Life Sciences so far, in Financings, Listings, Mergers. ## Investor discussion: ENDRA Life Sciences Members talk about ENDRA Life Sciences (NDRA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at ENDRA Life Sciences, newest first. Each line links the filing it comes from. 1. 2026-10-26 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1681682/000147793226006456/asp_425.htm) 2. 2026-08-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1681682/000121390026090027/ea0301717-10q_endra.htm) 3. 2026-06-25 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1681682/000121390026071804/ea029589901ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NDRA on TradingView](https://www.tradingview.com/symbols/NASDAQ-NDRA/). ## Listing details ENDRA Life Sciences Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NDRA, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: ENDRA Life Sciences Inc. - **Ticker**: NDRA - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/endra-life-sciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ENDRA Life Sciences (NDRA) news: offering and merger", 2026-10-31, https://aibio.space/companies/endra-life-sciences/